Andrew J Wiele1, Devaki Shilpa Surasi2, Priya Rao3, Kanishka Sircar3, Xiaoping Su4, Tharakeswara K Bathala5, Amishi Y Shah6, Eric Jonasch6, Vince D Cataldo7, Giannicola Genovese6,8, Jose A Karam9,10, Christopher G Wood9, Nizar M Tannir6, Pavlos Msaouel6,10. 1. Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. 2. Department of Nuclear Imaging, Division of Diagnostic Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. 3. Department of Pathology, Division of Pathology and Laboratory Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. 4. Department of Bioinformatics and Computational Biology, Division of Quantitative Sciences, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. 5. Department of Abdominal Imaging, Division of Diagnostic Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. 6. Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. 7. Mary Bird Perkins-Our Lady of the Lake Cancer Center, Baton Rouge, LA 70809, USA. 8. Department of Genomic Medicine, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. 9. Department of Urology, Division of Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. 10. Department of Translational Molecular Pathology, Division of Pathology and Laboratory Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Abstract
PURPOSE: To assess the efficacy and safety of bevacizumab plus erlotinib in patients with RMC. METHODS: We retrospectively reviewed the records of patients with RMC treated with bevacizumab plus erlotinib at our institution. RESULTS: Ten patients were included in the study. Two patients achieved a partial response (20%) and seven patients achieved stable disease (70%). Tumor burden was reduced in seven patients (70%) in total, and in three out of five patients (60%) that had received three or more prior therapies. The median progression-free survival (PFS) was 3.5 months (95% CI, 1.8-5.2). The median overall survival (OS) from bevacizumab plus erlotinib initiation was 7.3 months (95% CI, 0.73-13.8) and the median OS from diagnosis was 20.8 months (95% CI, 14.7-26.8). Bevacizumab plus erlotinib was well tolerated with no grade ≥4 adverse events and one grade 3 skin rash. Dose reduction was required in one patient (10%). CONCLUSIONS: Bevacizumab plus erlotinib is clinically active and well tolerated in heavily pre-treated patients with RMC and should be considered a viable salvage strategy for this lethal disease.
PURPOSE: To assess the efficacy and safety of bevacizumab plus erlotinib in patients with RMC. METHODS: We retrospectively reviewed the records of patients with RMC treated with bevacizumab plus erlotinib at our institution. RESULTS: Ten patients were included in the study. Two patients achieved a partial response (20%) and seven patients achieved stable disease (70%). Tumor burden was reduced in seven patients (70%) in total, and in three out of five patients (60%) that had received three or more prior therapies. The median progression-free survival (PFS) was 3.5 months (95% CI, 1.8-5.2). The median overall survival (OS) from bevacizumab plus erlotinib initiation was 7.3 months (95% CI, 0.73-13.8) and the median OS from diagnosis was 20.8 months (95% CI, 14.7-26.8). Bevacizumab plus erlotinib was well tolerated with no grade ≥4 adverse events and one grade 3 skin rash. Dose reduction was required in one patient (10%). CONCLUSIONS:Bevacizumab plus erlotinib is clinically active and well tolerated in heavily pre-treated patients with RMC and should be considered a viable salvage strategy for this lethal disease.
Authors: Jennifer S Isaacs; Yun Jin Jung; David R Mole; Sunmin Lee; Carlos Torres-Cabala; Yuen-Li Chung; Maria Merino; Jane Trepel; Berton Zbar; Jorge Toro; Peter J Ratcliffe; W Marston Linehan; Len Neckers Journal: Cancer Cell Date: 2005-08 Impact factor: 31.743
Authors: Rajyalakshmi Luthra; Keyur P Patel; Mark J Routbort; Russell R Broaddus; Jonathan Yau; Crystal Simien; Wei Chen; David Z Hatfield; L Jeffrey Medeiros; Rajesh R Singh Journal: J Mol Diagn Date: 2016-12-23 Impact factor: 5.568
Authors: Liwei Jia; Maria I Carlo; Hina Khan; Gouri J Nanjangud; Satshil Rana; Robert Cimera; Yanming Zhang; A Ari Hakimi; Amit K Verma; Hikmat A Al-Ahmadie; Samson W Fine; Anuradha Gopalan; S Joseph Sirintrapun; Satish K Tickoo; Victor E Reuter; Benjamin A Gartrell; Ying-Bei Chen Journal: Mod Pathol Date: 2019-04-12 Impact factor: 7.842
Authors: Pavlos Msaouel; Gabriel G Malouf; Xiaoping Su; Hui Yao; Durga N Tripathi; Melinda Soeung; Jianjun Gao; Priya Rao; Cristian Coarfa; Chad J Creighton; Jean-Philippe Bertocchio; Selvi Kunnimalaiyaan; Asha S Multani; Jorge Blando; Rong He; Daniel D Shapiro; Luigi Perelli; Sanjana Srinivasan; Federica Carbone; Patrick G Pilié; Menuka Karki; Riyad N H Seervai; Bujamin H Vokshi; Dolores Lopez-Terrada; Emily H Cheng; Ximing Tang; Wei Lu; Ignacio I Wistuba; Timothy C Thompson; Irwin Davidson; Virginia Giuliani; Katharina Schlacher; Alessandro Carugo; Timothy P Heffernan; Padmanee Sharma; Jose A Karam; Christopher G Wood; Cheryl L Walker; Giannicola Genovese; Nizar M Tannir Journal: Cancer Cell Date: 2020-04-30 Impact factor: 31.743
Authors: Daniel D Shapiro; Melinda Soeung; Luigi Perelli; Eleonora Dondossola; Devaki Shilpa Surasi; Durga N Tripathi; Jean-Philippe Bertocchio; Federica Carbone; Michael W Starbuck; Michael L Van Alstine; Priya Rao; Matthew H G Katz; Nathan H Parker; Amishi Y Shah; Alessandro Carugo; Timothy P Heffernan; Keri L Schadler; Christopher Logothetis; Cheryl L Walker; Christopher G Wood; Jose A Karam; Giulio F Draetta; Nizar M Tannir; Giannicola Genovese; Pavlos Msaouel Journal: Cancers (Basel) Date: 2021-11-30 Impact factor: 6.639